Moderna and Merck's Intismeran Vaccine Shows Promise Against Melanoma

A new vaccine called Intismeran has shown promise in preventing the recurrence of melanoma, the deadliest form of skin cancer. Developed by Moderna and Merck, the vaccine is designed for people who have already had melanoma.

The companies say that the vaccine uses individualized mRNA technology, similar to some coronavirus vaccines. This allows the vaccine to be tailored to each patient based on unique mutations within their tumors.

In current studies, Intismeran is being paired with Keytruda, and Phase 3 trial results suggest that it can stop the disease from returning or spreading.

Moderna and Merck emphasize that the vaccine is individualized, which could lead to more effective treatment for melanoma patients.